Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 313.75 GBp
Change Today -11.50 / -3.54%
Volume 29.3K
As of 3:45 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

skyepharma plc (SKP) Snapshot

Open
320.00 GBp
Previous Close
325.25 GBp
Day High
320.00 GBp
Day Low
313.75 GBp
52 Week High
12/1/14 - 377.50 GBp
52 Week Low
01/26/15 - 245.75 GBp
Market Cap
328.8M
Average Volume 10 Days
592.7K
EPS TTM
0.16 GBp
Shares Outstanding
104.8M
EX-Date
--
P/E TM
20.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for SKYEPHARMA PLC (SKP)

Related News

No related news articles were found.

skyepharma plc (SKP) Related Businessweek News

No Related Businessweek News Found

skyepharma plc (SKP) Details

Skyepharma PLC develops and sells oral and inhalation pharmaceutical products. The company’s inhalation products include flutiform, a multi-dose pressurized metered dose inhaler for the treatment of bronchial asthma; Anoro Ellipta and Incruse Ellipta multi-dose dry powder inhalers for the treatment of chronic obstructive pulmonary disease (COPD); and Relvar Ellipta/Breo Ellipta multi-dose dry powder inhaler for the treatment of asthma and COPD. It also offers Solaraze, a topical gel treatment for actinic keratosis; and Exparel, a bupivacaine injectable product for post-surgical pain management. The company’s oral drug delivery products comprise Paxil CR, an anti-depressant; Sular, a calcium channel blocker antihypertensive agent; Xatral OD, a selective alpha blocker for the treatment of BPH (urinary symptoms); Requip for Parkinson’s disease; Diclofenacratiopharm uno, a dual release diclofenac sodium formulation for pain/inflammation; and ZYFLO CR, an extended-release formulation of the oral asthma drug zileuton. Its oral drug delivery products also comprise Madopar DR, an oral treatment for Parkinson’s disease; Lodotra, a night-time release formulation of low dose prednisone for the treatment of morning stiffness associated with rheumatoid arthritis; Triglide, an oral treatment for elevated blood lipid disorders; and Coruno for the oral treatment of chronic angina pectoris. The company has partnerships with various companies, including GlaxoSmithKline, Sanofi, Mundipharma, and Kyorin worldwide. Skyepharma PLC was founded in 1910 and is headquartered in London, the United Kingdom.

92 Employees
Last Reported Date: 04/10/15
Founded in 1910

skyepharma plc (SKP) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 567.0K GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 74.0K GBP
Compensation as of Fiscal Year 2013.

skyepharma plc (SKP) Key Developments

Skyepharma PLC Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015; Provides Revenue Guidance for the Year 2015

Skyepharma PLC reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported revenue of £40.8 million against £34.4 million a year ago. Pre-exceptional operating profit was £12.5 million against £13.2 million a year ago. Operating profit was £12.5 million against £13.2 million a year ago. Profit before tax was £10.5 million against loss before tax of £18.1 million a year ago. Total profit for the period attributable to the parent was £9.1 million against total loss for the period attributable to the parent of £17.7 million a year ago. Diluted earnings per share were 8.6 pence against diluted loss per share of 27.0 pence a year ago. Pre-exceptional earnings per share diluted were 8.6 pence against 11.8 pence a year ago. Net cash generated by operating activities was £8.6 million against £8.7 million a year ago. Purchases of property, plant and equipment was £0.4 million against £0.3 million a year ago. Purchases of intangible assets was £0.9 million against £0.9 million a year ago. For the year 2015, the company expects continued substantial growth in revenues in 2015 compared with 2014, due to ongoing momentum from the products launched since March 2012, especially flutiform, EXPAREL and the GSK Ellipta-range of products, as well as the exceptional performance of Solaraze in the U.S. in first half of 2015.  Based on current forecasts by analysts who follow Pacira, the next sales milestone of $8.0 million (£5.1 million) receivable by the company, which is due when annual net sales of EXPAREL (on a cash received basis) reach $250 million, is expected to be triggered in 2016.

Skyepharma PLC, H1 2015 Earnings Call, Aug 26, 2015

Skyepharma PLC, H1 2015 Earnings Call, Aug 26, 2015

Skyepharma PLC to Report First Half, 2015 Results on Aug 26, 2015

Skyepharma PLC announced that they will report first half, 2015 results on Aug 26, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SKP:LN 313.75 GBp -11.50

SKP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $6.75 USD -0.12
Nektar Therapeutics $11.05 USD +0.18
Onxeo SA €3.85 EUR -0.06
Veloxis Pharmaceuticals A/S kr1.02 DKK -0.03
XenoPort Inc $6.75 USD +0.08
View Industry Companies
 

Industry Analysis

SKP

Industry Average

Valuation SKP Industry Range
Price/Earnings 20.6x
Price/Sales 4.2x
Price/Book 9.2x
Price/Cash Flow 19.5x
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SKYEPHARMA PLC, please visit www.skyepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.